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A simple, selective, rapid, and precise reverse-phase high-performance liquid chroma-
tography (RP-HPLC) method for the simultaneous estimation of rabeprazole (RP), pan-
toprazole (PP), and itopride (IP) has been developed. The compounds were well separated
on a Phenomenex C18 (Luna) column (250 mm  4.6 mm, dp ¼ 5 mm) with C18 guard column
(4 mm  3 mm  5 mm) with a mobile phase consisting of buffer containing 10 mM po-
tassium dihydrogen orthophosphate (adjusted to pH 6.8): acetonitrile (70:30 v/v) at a flow
rate of 1.0 mL/min and ultraviolet detection at 288 nm. The retention time of RP, PP, and IP
were 5.35, 7.92, and 11.16 minutes, respectively. Validation of the proposed method was
carried out according to International Conference on Harmonisation (ICH) guidelines.
Linearity range was obtained for RP, PP, and IP over the concentration range of 2.5e25, 1
e30, and 3e35 mg/mL and the r2 values were 0.994, 0.978, and 0.991, respectively. The
calculated limit of detection (LOD) values were 1, 0.3, and 1 mg/mL and limit of quantitation
(LOQ) values were 2.5, 1, and 3 mg/mL for RP, PP, and IP correspondingly. Thus, the current
study showed that the developed reverse-phase liquid chromatography method is sensi-
tive and selective for the estimation of RP, PP, and IP in combined dosage form.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction
Rabeprazole (RP), [2-[[[4-(3-methoxypropoxy)-3-methyl-2-
pyridinyl]-methyl] sulfinyl]-1H-benzoimidazole] (Fig. 1), is
used for the treatment of severe gastroesophageal refluxarmaceutical Technolog
.P. Ekambaram).
ministration, Taiwan. Publdisease (GERD) and peptic ulcer. Pantoprazole (PP), [6-
(difluoromethoxy)-2-[[(3, 4-dimethoxy-2-pyri-dinyl)-methyl]
sulfinyl] 1-benzoimidazole] (Fig. 1), is used for the treatment of
erosive esophagitis associated with GERD. Both RP and PP are
proton pump inhibitors and they inhibit gastric acid secretion
by targeting the gastric acid pump Hþ Kþ adenosiney, Anna University, BIT Campus, Tiruchirappalli e 620 024,
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license. 
Fig. 1 e Chemical structures of (A) rabeprazole, (B)
pantoprazole, and (C) itopride.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 2 ( 2 0 1 4 ) 5 2 0e5 2 6 521triphosphatase of the parietal cell. Proton pump inhibitors
also are effective in treating patients with Zollinger-Ellison
syndrome [1]. Itopride (IP), [N-[4-[2-[dimethyl amino ethoxy]
phenyl] methyl]-3,4-dimethoxybenzamide (Figure 1), inhibits
the dopamine D2 receptor at the parasympathetic nerve ends
and increases the release of acetylcholine, thereby increasing
the esophageal and gastrointestinal motility. It also exerts an
antiemetic action [2].
The combination of PP inhibitor and IP iswidely available in
the market for the treatment of gastrointestinal disorders. In
general, these kinds of multicomponent dosage forms are
useful for effective therapy and augment patient compliance.
A range of analytical techniques, such as ultraviolet (UV)-
visible spectrophotometry, high-performance liquid chroma-
tography (HPLC), high-performance thin layer chromatog-
raphy (HPTLC), and liquid chromatography-mass
spectrometry (LC-MS) were reported in the literature for the
determination of RP [3e10], PP [11e16], and IP [17e20] in dosage
forms and biological samples in separate as well as in combi-
nation. Nevertheless, there is no information on the HPLC
method for the concurrent determination of these drugs in
combined dosage forms. The current study describes a simple,
precise, and accurate reverse-phase high-performance liquid
chromatography (RP-HPLC) method for the simultaneous
estimation of RP, PP, and IP in combined dosage forms.2. Materials and methods
2.1. Chemicals
Acetonitrile (HPLC grade), orthophosphoric acid [analytical
reagent (AR) grade], sodium hydroxide (AR grade), andammonium acetate (AR grade) were purchased from E. Merck
(India) Ltd. Worli, Mumbai, India. All active pharmaceutical
ingredients (APIs) RP, PP, and IP as reference standards were
obtained from Medley Pharmaceuticals Limited, Mumbai,
India (99.7e99.9% purity).2.2. Equipment
Shimadzu's HPLC quaternary system with UV-visible detector
(LC-10AT VP) and 7725i injector was used for method devel-
opment and validation.2.3. Method development and optimization of
chromatographic conditions for separation
The chromatographic condition was optimized by using
different columns,mobile phase composition, pH (6.6, 6.8, and
7.0), wavelength (285, 288, and 290), flow rate (0.9, 1.0, and 1.1),
column temperature (ambient to 45C), and injection volume
(10, 20, 30, and 50 mL).2.4. Sample preparation
2.4.1. Chemical form of the APIs
RP sodium is a white to slightly yellowish-white solid. PP so-
dium is a white to off-white crystalline powder. IP hydro-
chloride is a white crystalline solid.
2.4.2. Preparation of RP, PP, and IP stock solutions
Stock solution was prepared by weighing 10mg each of RP, PP,
and IP standards in a 10-mL volumetric flask, dissolving in
mobile phase, and diluting to volume with the same mobile
phase up to 10 mL and retained as stock solution. Further di-
lutions were made with mobile phase.
2.4.3. Preparation of RP, PP, and IP standard dilutions
One milliliter from the stock solutions of RP, PP, and IP were
transferred into a 10-mL volumetric flask separately and
further diluted up to 10 mL with the solvent. Then 1 mL of RP,
1.5 mL of PP, and 2 mL of IP solutions were transferred into a
10-mL volumetric flask and diluted up to 10 mL separately to
attain the final concentrations of 10 mg/mL, 15 mg/mL, and
20 mg/mL of RP, PP, and IP, respectively.
2.4.4. Preparation of mixed standard solutions
From the aforementioned standard stock solution, mixed
standard solution was prepared by dissolving appropriate
concentration of the stocks in the mobile phase and used for
the estimation of individual drugs from the combination.
2.4.5. Preparation of the sample solution
The label claim of the dosage form includes 10 mg of RP so-
dium, 40 mg of PP sodium, and 50 mg of IP hydrochloride.
Twenty tablets of RP, PP, and IP available as combination
dosage forms were weighed and powdered. An amount of the
powder equivalent to one tablet was weighed accurately and
mixed with the mobile phase in a 100-mL volumetric flask,
sonicated for 5 minutes and filtered through 0.2 m membrane
filter to remove insoluble matter. One milliliter of the filtrate
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2.4.6. Method for the estimation
With the optimized chromatographic conditions, a steady
baseline was recorded. After stabilization of the baseline for
about 30minutes, successive aliquots of the standard solution
of the same concentration were injected and chromatogram
was recorded until the reproducibility of the peak areas was
satisfactory. This procedure was repeated using the sample
solution so that duplicate injection of the sample solution was
bracketed by injection of the standard solution.
The response factor of the standard peak and sample peak
was obtained and the amount of each drug in the sample was
determined. This procedure was repeated six times.
The concentration of each drug in the multicomponent
dosage form was calculated using the formula (1):
Concentration of drug ¼ Response factor of the sample
Response factor of the standard
 Concentration of standard (1)
2.5. Validation of the method
The developed method was validated for as per ICH Q2 (R1)
guidelines [21] for various parameters such as accuracy, pre-
cision, linearity, robustness, limit of detection (LOD), limit of
quantitation (LOQ), and stability.
2.5.1. Accuracy
The accuracy of the RP-HPLC method was evaluated by
selecting three different concentrationsdlower quantitation
limit (LQC), medium quantitation limit (MQC), and higher
quantitation limit (HQC). In each concentration, a minimum
of six injections were given and the amount of the drugs
present, percentage recovery, and related standard deviation
were calculated. The percentage recovery was calculated
using the formula (2):
Percentage recovery ¼ ½b a
c
 100 (2)
Where a is the amount of the sample drug, b is the amount of
sample drug and the standard drug and c is the amount of
standard drug added.
2.5.2. Precision
The precision of the developed method was studied by per-
forming interday and intraday variations. Intraday variations
were studied by consecutively injecting the standard and
sample solutions for six times on the same day. Interday
variations were studied by estimating the drugs present in the
multicomponent dosage forms on three different days. Six
injections of standard and sample solutions were made every
day. The amount of each drug, percentage content, standard
deviation, and percentage coefficient of variation were
calculated.
2.5.3. Linearity and range
The six series of standard solutions were selected for assess-
ing linearity range. The calibration curve was plotted usingpeak area versus concentration of the standard solution and
the regression equations were calculated. The least squares
method was used to calculate the slope, intercept and corre-
lation coefficient.
2.5.4. LOD and LOQ
The LOD and LOQ of RP, PP, and IP were determined by
injecting progressively lower concentrations of the standard
solutions into the HPLC column using the optimized chro-
matographic conditions in accordance with 3.3 s/n and 10 s/n
criteria, respectively, where s/n indicates signal-to-noise
ratio.
2.5.5. Robustness
For demonstrating the robustness of the method, slight vari-
ations in the optimized conditions were done and the stan-
dard solution was injected. The variations made were ±2% in
the ratio of acetonitrile in themobile phase,±0.2 unit in the pH
of the buffer, ±0.1mL/min in the flow rate, ±5C in the column
temperature, and ±1 nm in the wavelength. The separation
factor, retention time and peak asymmetry were calculated.
2.5.6. Stability
The mobile phase, standard solution, and the sample solution
were subjected to long-term (3 days) stability studies. The
stability of these solutionswas studied by storing the standard
solution for 3 days and observing for changes in the separa-
tion, retention, and asymmetry of the peaks, which were then
compared with the pattern of the chromatogram of freshly
prepared solution.3. Results and discussion
Proper selection of the HPLCmethod depends on the nature of
the sample (ionic or ionizable or neutral molecule), its mo-
lecular weight, and solubility. The drugs selected for the cur-
rent study are polar in nature; hence, RP-HPLC was selected
for its separation because of its simplicity and suitability.
3.1. Optimization of the chromatographic condition
Method optimization for the simultaneous estimation of the
combination of RP, PP, and IP in multicomponent dosage
forms was carried out.
3.1.1. Column selection
Experiments with different columns were conducted to ach-
ieve best separation of analyte peak with other blank and
placebo peaks. It was found that the peak shape, retention
time, tailing factor, and column efficiency were good with
Phenomenex C18 column (250  4.6 mm, dp ¼ 5 mm) with C18
guard column (4 mm  3 mm  5 mm).
3.1.2. Mobile phase composition
On the basis of the solubility study, 10 mM potassium dihy-
drogen orthophosphate was decided as the buffer preparation
to be used. A mixture of 10 mM potassium dihydrogen
orthophosphate and the organic solvents in different pro-
portions were tested, as variation in the mobile phase
Fig. 2 e The representative chromatogram. The simultaneous estimation of rabeprazole, pantoprazole, and itopride, the
peaks at the retention time of 5.33, 7.93, and 11.19 minutes, respectively.
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graphic performance. Decreasing the organicmodifier content
resulted in decrease in the retention time of the analyte but
had no effect on analyte response. When experiments were
performed with methanol instead of acetonitrile as organic
modifier in themobile phase, late elution of analyte with peak
tailing and increased column pressure were observed. Hence,
acetonitrile was selected as an organic modifier. Many trials
on the composition of buffer and organic solvents were made
to decide the ultimate composition of the mobile phase as
buffer:acetonitrile (70:30).
Based on the peak shape, peak symmetry, and retention
time, the flow rate of 1 mL/min, and ambient column tem-
perature were also optimized.
3.1.3. Detection wavelength
The sensitivity of a HPLCmethodwith UV detection depends on
the proper selection of detection wavelength, which can be
determined by recording overlaid UV spectra. In the current
study, solutions containing 10 mg/mL of RP, 15 mg/mL of PP, and
20mg/mLof IPwereprepared inmobilephaseandscannedunder
200e400 nm of UV region to record the overlaid UV spectra.Table 1 e Accuracy (recovery, %) studies expressed in concentr
three different concentrations.
Study no. Rabeprazole
2.5 10 25 1
1. 97.9 102.2 104.67 98.76
2. 96.55 98.12 99.43 99.15
3. 96.24 103.16 102.55 99.67
4. 98.65 106.08 101.68 101.25
5. 95.07 101.07 103.09 101.87
6. 101.1 100.33 105.05 100.45
Avg 97.58 101.82 102.74 100.19
%RSD 2.13 2.70 2.06 1.21
Avg ¼ average; RSD ¼ relative standard deviation.3.1.4. pH of the buffer
pH plays an important role in achieving the chromatographic
separation as it controls the elution properties by controlling
ionization characteristics. The pKa values for RP and PPwere 5
and 3.8, respectively. Potassium dihydrogen orthophosphate
buffer (10 mM) was selected based on the solubility studies.
Various trials on pH were made to determine the optimized
pH at which the APIs are separatedwell. At pH 6.8, peak shape,
peak tailing and theoretical plate count were found to be
satisfactory; hence, 6.8 was decided as the pH of the buffer. A
tolerable limit of pH 6.8 ± 0.1 was optimized using a pHmeter.
In order to determine the adequate resolution and repro-
ducibility of the proposed method, suitability parameters
including retention time, plate number, and tailing factor
were investigated and were found to be 5.33 min, 8670, 0.9 for
RP; 7.93, 8550, 1.05 for PP; and 11.19, 7980, 1.09 for IP, respec-
tively, which indicates the method suitability.
The optimized chromatographic conditions are
mobile phase concentrationdbuffer (10 mM KH2PO4): Aceto-
nitrile (ACN) 70: 30% v/v, pH 6.8, 288 nm as detection wave-
length, 1.0 mL/min flow rate, ambient column temperature,
50 mL injection volume.ation (mg/mL) of rabeprazole, pantoprazole, and itopride at
Pantoprazole Itopride
15 30 3 20 35
100.78 102.01 99.97 99.92 99.93
101.53 101.98 100.02 100.07 101.98
99.18 99.59 100.05 100.12 102.01
98.76 99.43 99.92 99.98 101.78
102.08 98.68 99.98 99.89 101.56
101.86 98.75 99.95 99.91 100.65
100.69 100.07 99.98 99.98 101.31
1.40 1.53 0.04 0.09 0.83
Table 2 e Intraday and interday assay precision analysis
data of the proposed method.
Actual concentration Measured concentration
(mg/mL), RSD (%) (n ¼ 6)
intraday interday
Rabeprazole
2.5 2.56, 0.82 2.49, 0.66
25 24.65, 0.89 24.86, 0.88
45 45.09, 0.92 44.89, 0.99
Pantoprazole
1 0.99, 0.42 0.95, 0.99
15 14.95, 0.22 14.92, 0.76
30 30.02, 0.88 29.89, 0.86
Itopride
3 2.99, 0.84 3.09, 0.65
20 19.86, 0.95 20.09, 1.00
35 34.86, 0.62 35.00, 0.92
RSD ¼ relative standard deviation.
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3.2.1. Specificity
The specificity of the existing method of analysis by HPLC is
shown in Figure 2; the complete and clear separation of RP, PP,
and IP was observed without any interference in retention
time.
3.2.2. Accuracy
The accuracy of the method was determined by recovery ex-
periments. Recovery studies were carried out with six in-
jections and three different concentrations. The percent
recovery, mean, and relative standard deviation (% RSD) were
calculated and presented in Table 1. APIs with concentration
2.5, 10, and 25 mg/mL of RP; 1, 15, and 30 mg/mL of PP; and 3, 20,
and 35 mg/mL of IP were prepared. The test solution was
injected six times for each spike level and the assay was
performed as per the test method. Analysis of the results has
shown that the percentage recovery valueswere close to 100%Table 3 e Robustness study of the proposed method.
Factor Level
Rab
Flow rate (mL/min) 0.9 98
1.0 99
1.1 98
pH of mobile phase 6.6 98
6.8 98
7.0 98






Percentage organic solution 28 99
30 97
32 97
RSD ¼ relative standard deviation.and also the RSD values were less than ±5%. The accuracy and
reliability of the developed method was established.
3.2.3. Precision
The precision of the method was demonstrated by interday
and intraday variation studies at various concentrations:
2e25 mg/mL for RP, 1e30 mg/mL for PP, and 3e35 mg/mL for IP,
and their data are summarized in Table 2. The lower RSD%
values (<1.00) indicate good precision of the developed
method.
3.2.4. Linearity and range
Six series of standard solutions were selected for assessing
linearity range (2.5e25 mg/mL for RP, 1e30 mg/mL for PP, and 3e
35 mg/mL for IP). The calibration curve was plotted using
response factor versus concentration of the standard solution.
From the calibration curve, the slope and intercept were
calculated. The data obtained from the linearity range are
depicted in the graph and the results show the Y intercept as
187.6x 11.31 for RP, 82.77xþ 1216 for PP and 75.29xþ 1374 for
IP with higher correlation coefficient r value 0.994, 0.978, and
0.991 for RP, PP, and IP respectively.
3.2.5. LOD and LOQ
The LOD and LOQ of the compounds were determined by
injecting progressively lower concentrations of the standard
solutions into the HPLC column using the optimized chro-
matographic conditions. The LOD values were found to be 1,
0.3, and 1 mg/mL for RP, PP, and IP, respectively. The LOQ
values were found to be 2.5, 1, and 3 mg/mL for RP, PP, and IP,
respectively.
3.2.6. Robustness
The robustness was evaluated by making slight variations in
the optimized conditions such as flow rate, pH of mobile
phase, column temperature, wavelength, and percentage of
organic solvent. The mixed standard solution was injected in
five replicates and %RSD of assay was calculated for each
condition. The results obtained (Table 3) as a cause of smallMean (Assay, %) RSD (n ¼ 3)
eprazole Pantoprazole Itopride
.5, 1.12 98.8, 0.55 97.6, 1.11
.0, 0.68 98.2, 0.82 96.8, 0.95
.7, 0.96 99.3, 0.86 99.3, 0.92
.7, 0.96 99.6, 0.95 99.6, 0.82
.4, 1.82 98.3, 0.75 98.4, 0.99
.8, 0.95 97.5, 0.89 99.3, 0.66
.8, 0.96 98.9, 0.82 97.5, 0.95
.4, 1.25 98.6, 1.02 97.6, 0.94
.8, 1.28 97.3, 0.98 99.6, 0.60
0.2, 0.64 100.8, 0.87 98.4, 1.09
.8, 0.95 98.4, 0.78 99.5, 0.97
.2, 0.88 98.8, 0.95 98.9, 1.08
.2, 0.92 99.6, 0.95 99.5, 0.52
.6, 0.88 101.3, 0.55 98.7, 0.96
.6, 1.08 99.2, 0.83 98.8, 0.96
Table 4 e Solution stability studies.
Study no. (Percentage deviation between actual and
stored recovery)
Rabeprazole Pantoprazole Itopride
1 2.58 0.25 0.46
2 2.32 0.19 0.35
3 2.28 0.17 0.62
4 2.49 1.78 0.92
5 1.05 0.36 0.55
6 1.08 0.89 0.53
Average 0.61 0.30 0.36
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that the analytical method is robust.
3.2.7. Stability
The stability of the drug solutions was assessed by main-
taining the solution at room temperature for 3 days and
observing for changes in the chromatographic pattern as well
as the content of the solution on comparison with the freshly
prepared solution. The results were expressed in terms of
percent deviation between actual and stored recovery
(Table 4).4. Conclusion
A convenient and rapid simultaneous RP-HPLC method has
been developed for the estimation of RP, PP, and IP. Best sep-
arationwas achieved on a Phenomenex C18 (250mm 4.6mm
internal diameter (i.d.), 5 m) with C18 guard column
(4 mm  3 mm  5 mm), 10 mM potassium dihydrogen ortho-
phosphate (adjusted to pH 6.8): acetonitrile (70:30 v/v) at a flow
rate of 1.0 mL/min as mobile phase and 288 nm as detection
wavelength. The method was validated in terms of accuracy,
precision, specificity, linearity, robustness, and solution sta-
bility according to ICH guidelines. The proposed method is
simple, fast, accurate, and precise for the simultaneous
quantification of RP, PP, and IP in bulk drugs and finished
products as well as for routine analysis in quality control.Conflicts of interest
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